Business Wire

Mentice, Together with the ASSERT Centre at University College Cork, Ireland, to Introduce State-of-the-Art Training Solution for Acute Ischemic Stroke (AIS)

Del

The ASSERT Centre at University College Cork in Ireland is to host a new mechanical thrombectomy training course featuring Mentice’s high-fidelity endovascular training solution. The training solution is the result of a project part-financed by Vinnova, Sweden’s national innovation agency.

ASSERT (Application of Science to Simulation-based Education and Research on Training) plans to hold the two-day course June 29-30. The course combines high-fidelity simulators from Mentice with a ‘proficiency-based progression’ training method.

“This method,” says Mentice CEO Göran Malmberg, “brings system generated objective assessment into the training process. Trainees must demonstrate proficiency in a series of carefully selected training milestones before progressing. These milestones are assessed by the system which makes them entirely objective. It’s a critical development, the number of endovascular interventions for stroke is set to rise dramatically worldwide. Proficiency-based progression with simulation based structured training will not only help to radically reduce the cost of skills development but also help scale this procedure in a safe way.”

Mechanical thrombectomy—a revolutionary new minimally invasive procedure in which a clinical device is introduced into the affected brain’s vasculature to mechanically remove a blood clot—is now recognized as the preferred treatment for acute ischemic stroke. “The shift to interventional treatment of stroke is a fantastic health opportunity that will have the ability to save hundreds of thousands of patients annually worldwide,” comments Malmberg. “This promising procedure will face a multitude of challenges including early diagnosis of stroke and of course effective dispatch of patients to treatment. In addition, effective training of new and existing teams and operators is certainly one big challenge of a safe roll-out, which is where Mentice, ASSERT and proficiency-based progression can really contribute.”

The Mentice training solution deployed by ASSERT has been developed in collaboration with recognized neurovascular specialists Professor Thomas Liebig, Dr. Markus Holtmannspötter and Dr. Robert Crossley, as well as with technology-enhanced learning expert Professor Tony Gallagher of ASSERT.

“Mechanical Thrombectomy for acute stroke,” says Professor Tony Gallagher of ASSERT, “is a life-changing treatment for many gravely ill patients. The success of the treatment is determined in no small part by the skills of the clinician performing the procedure.”

A larger panel with more than 20 experts from 7 countries have been highly involved in validating this new training method which will be shown for the first time during this two-day course, June 29-30.

“We are privileged to have the course facilitated by leading neurovascular specialists at the ASSERT Centre and are confident that this program will be the first of many,” says ASSERT Director/Clinical Lead Professor Barry O’Reilly.

About Mentice

Mentice is a world leader in medical simulation, providing qualified solutions for training, education and assessment opportunities. With a focus on minimally invasive techniques and procedures, Mentice develops simulation systems for training in a safe environment within the fields of endovascular intervention and minimally invasive surgery. The advantages of training with Mentice solutions are well documented enhancing clinical performance, reducing cost, and, in the long term, improving patient safety. For more information please visit www.mentice.com

About ASSERT

The ASSERT Centre, College of Medicine and Health, University College Cork Ireland is a new state of the art facility dedicated to cadaveric and simulation based healthcare training and research. ASSERT provides both the facility and services ideally suited to conducting all types of training for healthcare practitioners, specialists or teams. ASSERT is ideally placed as the bridge that links clinicians, industry and healthcare research institutes both locally and internationally. For more information, please see www.ucc.ie/assert

Contact information

Mentice AB
Hiral Chavda, Marketing Communications Manager
+46 (0) 31 339 94 94
hiral.chavda@mentice.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Wealthify Selects Moody’s Analytics Modeling Technology to Support Its Online Investment Proposition22.6.2018 07:00Pressemelding

Moody’s Analytics, a leading provider of financial intelligence, announced today that its technology has been selected by Wealthify, an innovative provider of digital wealth management services. Wealthify will be using the Moody’s Analytics Wealth Scenario Generator (“WSG”) to assist clients in making informed decisions on their investment plans. The Moody’s Analytics WSG is a modeling engine that supports financial planning and investment decision making. It has been integrated into Wealthify’s online investment proposition to illustrate a likely range of financial outcomes based on the investment style and level of investment a customer selects. This allows investors to better appreciate the balance between risk and return. “Our decision to work with Moody’s Analytics was driven by their comprehensive modeling and technology offering,” said Michelle Pearce, co-founder and Chief Investment Officer at Wealthify. “Their solution provides the robust economic assumptions required for our

Loxam Announces the Acquisition of Italian Powered Access Rental Specialist Nove22.6.2018 07:00Pressemelding

Loxam Group (“Loxam”) announces the acquisition of the Italian powered access rental company No.Ve. S.r.l. (“Nove”) from Haulotte Group S.A. (“Haulotte”). Nove was founded in 1998 and was controlled by Haulotte since 2006. The company is headquartered in Rome and has 45 employees in 6 branches throughout Italy. Following the acquisition of Nacanco last year, this transaction enables Loxam to consolidate its leading position in the Italian powered access rental market. Gérard Déprez, President of Loxam states: “I am delighted to welcome the skilled and experienced Nove team into the Loxam group. Nove is a long-established player in Italy and operates an equipment range very well known to the Loxam Group and we will be able to share our mutual expertise. We will join forces to provide our customers with the best service through an expanded network, and build a reference company in the Italian equipment rental market.” “The divestment of Nove is in line with Haulotte strategic targets and

OpenGate Capital Completes Sale of NorPaper Group to Gemayel Freres & Chaoui Industriel Group22.6.2018 06:00Pressemelding

OpenGate Capital, a global private equity firm, announced today that it has completed the sale of one of its legacy, pre-fund investments, NorPaper Group (“NorPaper”), to Gemayel Freres & Chaoui Industriel Group, a Lebanon-based business specialized in recycled corrugated cardboard and packaging products. Terms of the transaction were not disclosed. OpenGate Capital acquired NorPaper from Canadian paper conglomerate, Cascades, in 2011. NorPaper is a leading producer of white top testliner paper that is sold to European packaging manufacturers. Realizing an opportunity to increase capacity within NorPaper, OpenGate completed an accretive, add-on acquisition in February of 2015 of DS Smith Packaging Papeterie de Nantes SAS (“Nantes”), a division of DS Smith, Plc (LON: SMDS). Integrated into NorPaper, Nantes broadened the product portfolio and added 50kT per year of production capacity through its white top testliner paper made from 100% recycled fiber with best in class quality and print

First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality21.6.2018 20:24Pressemelding

Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) announced today that the world’s first AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China has successfully completed initial criticality. “Today we completed the final major milestone before commercial operation for Westinghouse’s AP1000 nuclear power plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “We are one step closer to delivering the world’s first AP1000 plant to our customer and the world – with our customers, we will provide our customers in China with safe, reliable and clean energy from Sanmen 1.” Following initial criticality will be connection to the electrical grid. Once plant operations begin at Sanmen 1, it will be the first AP1000 nuclear power plant in operation, offering innovative passive safety system technology, multiple layers of defense and advanced controls for unequaled reliability and safety. Commentin

Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant21.6.2018 20:07Pressemelding

Westinghouse Electric Company and its customers, China State Nuclear Power Technology Corporation (SNPTC) and Shangdong Nuclear Power Company Limited (SDNPC) announced today that Haiyang Unit 1, the AP1000 nuclear power plant located in Haiyang, Shandong Province, China, has begun to load fuel. “This is a great day for Westinghouse, our China partners and the nuclear industry. Haiyang Unit 1 continues to demonstrate our ability to deliver safe, innovative solutions for power generation,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. He added, “Westinghouse will continue to deploy AP1000 technology throughout the world and demonstrate our technical leadership in the nuclear energy industry.” Fuel load at Haiyang Unit 1 commenced at 7:36 p.m. (GMT+8) today. Earlier this summer, in preparation for fuel load, Haiyang Unit 1 successfully completed the necessary testing and regulatory reviews conducted by China’s National Nuclear Safety Administration (NNS

Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 18:23Pressemelding

Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo